Management of home blood pressure by amlodipine combined with angiotensin II receptor blocker in type 2 diabetes

Circulation Journal

Volumn 76, Issue 9, 2012, Pages 2159-2166

  Miyauchi, Katsumi ^a   Yamazaki, Tsutomu ^b   Watada, Hirotaka ^c   Tanaka, Yasushi ^d   Kawamori, Ryuzo ^c   Imai, Yutaka ^e   Ikeda, Shunya ^f   Kitagawa, Akira ^g   Ono, Yasuhiro ^h   Murayama, Fumio ⁱ   Choi, Jong Bock ^b   Suwa, Satoru ^c   Hayashi, Dobun ^j   Kishimoto, Junji ^k   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOHOKU UNIVERSITY   (Japan)

^f INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^g Kanazawa Medical Clinic   (Japan)

^h Takagi Hospital   (Japan)

ⁱ International University of Health and Welfare   (Japan)

^j Nippon Yusen Kaisha (NYK Line)   (Japan)

^k KYUSHU UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Angiotensin II receptor blocker; Calcium channel blocker; Home blood pressure; Hypertension; Type 2 diabetes

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; HEMOGLOBIN A1C; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

AGED; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPHYGMOMANOMETER; SYSTOLIC BLOOD PRESSURE;

AGED; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 84865479254     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1406     Document Type: Article

References (23)

1. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 2001; 37: 1053-1059.
2. Asman G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation 2002; 105: 310-315.
3. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al and for the HOT Study Group. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
4. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, et al; for The Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-684.
5. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al; for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 2000; 36: 646-661.
6. McFarlane SI, Jacober SJ, Winer N, Kaur J, Castro JP, Wui MA, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002; 25: 718-723.
7. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006; 354: 2368-2374.
8. Mallick S, Kanthety R, Rahman M. Home blood pressure monitoring in clinical practice: A review. Am J Med 2009; 122: 803-810.
9. Brooks CS, Sowers JR. Importance of achieving lower blood pressure in hypertensive patients with diabetes. Hypertension 2004; 44: 614-615.
10. Kawamori R, Daida H, Tanaka Y, Miyauchi K, Kitagawa A, Hayashi D, et al. Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J). BMC Cardiovasc Disord 2006; 6: 39-44.
11. Ueshima K, Oba K, Yasuno S, Fujimoto A, Tanaka S, Ogihara T, et al. Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients: Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Circ J 2011; 75: 2411-2416.
12. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 29: 1342-1349.
13. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al; for the ACCOMPLISH Trial Investigators. Benazepril plus amlodip ine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
14. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
15. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
16. Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, et al; ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913.
17. Park SJ, Park JB, Choi DJ, Youn HJ, Park CG, Ahn YK, et al. Detection of masked hypertension and the 'mask effect' in patients with well-controlled office blood pressure. Circ J 2011; 75: 357-365.
18. Niiranen TJ, Hänninen MR, Johansson J, Reunanen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: The Finn-Home study. Hypertension 2010; 55: 1346-1351.
19. Sakuma M, Nakamura M, Tanaka F, Onoda T, Itai K, Tanno K, et al. Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population. Circ J 2010; 74: 792-797.
20. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Lüscher TF. Vasopeptidase inhibitors: A new therapeutic concept in cardiovascular disease? Circulation 2001; 104: 1856-1862.
21. Nakagawa N, Fujino T, Kabara M, Matsuki M, Chinda J, Kikuchi K, et al; NICE-Combi Study Group. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate. Hypertens Res 2011; 34: 1121-1126.
22. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-429.
23. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.